US4118478A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Vaccine manufacture for active immunization containing hepatitis B surface antigen and associated antigen
Assignee: New York Blood Center
•
Filing: 1977-02-24
•
Granted: 1978-10-03
•
Expires: 1997-02-24
Abstract
Abstract A process for preparing a vaccine containing unprecipitated filaments and hepatitis B Dane particle specific antigens by removal from a blood serum of other proteinaceous matter such that the serum contains less than 10% proteinaceous matter other than that associated with hepatitis B surface antigen or the filament or Dane particle specific antigen. Any virus present is inactivated, and the antigenous mass is diluted with a physiologically acceptable medium.
Inventors
- 👤 Alfred M. Prince
- 👤 John Vnek
- 👤 Robert A. Neurath
- 👤 Christian Trepo
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 10:05
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61K; A61K39/00; C12; C12N; C12N2730/00; C12N2730/00011; C12N2730/10011; C12N2730/10111; C12N2730/10122
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
133 words
A method of manufacturing a vaccine against hepatitis which comprises: A. obtaining the blood serum of a chronic carrier of hepatitis BsAg which blood serum contains HBsAg associated particles of a size of 16 to 50 nm of which at least some are in the range of 30-50 nm and is substantially free of anti-HBs and contains e-antigen and abundant Dane particles and which has no dectectable anti-e antibody, at least 1 percent of said particles being characterized by the presence of free, uncombined and unprecipitated e-antigen; B. removing other proteinaceous matter from said serum such that the serum contains less that 10% of proteinaceous matter other than that associated with HBsAg or e-antigen; C. inactivating any virus in the serum; and D. diluting the antigen containing serum with a physiologically acceptable medium.
Claim 2
Independent Claim
133 words
A method of manufacturing a vaccine against hepatitis which comprises: A. obtaining the blood serum of a chronic carrier of hepatitis BsAg which blood serum contains HBsAg associated particles of a size of 16 to 50 nm of which at least some are in the range of 30-50 nm and is substantially free of anti-HBs and contains e-antigen and abundant Dane particles and which has no dectectable anti-e antibody, at least 1 percent of said particles being characterized by the presence of free, uncombined and unprecipitated e-antigen; B. removing other proteinaceous matter from said serum such that the serum contains less that 10% of proteinaceous matter other than that associated with HBsAg or e-antigen; C. inactivating any virus in the serum; and D. diluting the antigen containing serum with a physiologically acceptable medium.
Claim 3
Dependent Claim
38 words
A process according to claim 1 wherein the resultant product is thereafter introduced into a human or chimpanzee in order to induce production of anti-HBs and anti-e as well as immunity against subsequent exposure to hepatitis B virus.
Claim 4
Dependent Claim
214 words
A method according to claim 1 wherein step B is performed by maintaining the pH of the blood material in the range of 4.4 to 4.7; mixing said material, while its pH is being contained in said range, with approximately 3.0 to 4.5 weight percent polyethylene glycol based on the total weight of the admixture, to produce a precipitate containing type B hepatitis antigen containing HBsAg and e-antigen; separately recovering said precipitate, adding a sufficient amount of water thereto to present intermediate free material having a type B hepatitis antigen concentration the same or higher than in the original blood material; causing the pH of said intermediate material to be in the range of approximately 4.9 to 5.1 thereby producing a precipitate containing non HB associated proteinaceous material, and polyethylene glycol, and a fluid phase containing type B hepatitis/e -antigen particles; separately recovering said fluid phase and adjusting the pH thereof to within the range of approximately 4.4 to 4.7; mixing the said fluid phase, while maintaining its pH within said range, with approximately 3.0 to 4.5 weight percent polyethylene glycol based on the total weight of said mixture, to produce a precipitate containing purified HBsAg/e particles; and recovering said purified HBsAg/e-containing material having proteinaceous filamentous or Dane particles containing unprecipitated free, uncombined e-antigen.
References Cited (Backward Citations)
US4017360A
Cited
US4024243A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-10-02 | 1982-04-03 | 1982-10-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-10-02 | 1986-04-03 | 1986-10-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-10-02 | 1990-04-03 | 1990-10-03 | $7700.00 | Window Closed / Lapsed |